![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Australia’s TGA Clears ResApp Health’s Wearable Cough Monitor
Australia’s TGA Clears ResApp Health’s Wearable Cough Monitor
![AustralianTherapeutic Goods Administration (TGA) Australian](https://www.fdanews.com/ext/resources/test/Device_Images/TGA-logo.gif?t=1589234466&width=430)
ResApp Health has received clearance from Australia’s Therapeutic Goods Administration (TGA) for its wearable cough-monitoring system.
The clip-on device provides 24/7 monitoring of a patient using an algorithm to analyze cough sounds. It identifies more than 93 percent of cough events and has a false-positive rate of less than 1 percent.
Brisbane-based ResApp said it plans to explore the device’s capabilities and first intends to put the device through clinical trials to evaluate its ability to measure cough frequency.
Upcoming Events
-
21Oct